Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: A review of the literature involving over 9,000 patients

Applied Immunohistochemistry and Molecular Morphology

Volumn 4, Issue 2, 1996, Pages 106-116

  Barbareschi, Mattia ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Breast neoplasm; Immunohistochemistry; p53 protein; Prognosis; Tumor suppressor genes

Indexed keywords

PROTEIN P53;

BREAST CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0029948848     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Lane DP. p53: the guardian of the genome. Nature 1992;358: 15-6.
2. Harris CC, Hollstein M. Clinical implication of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
3. Eyfjord JE, Thorlacius S, Steinersdottir M, Valgardsdottir R, Ogmondsdottir HM, Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 1995;55:645-51.
4. Chang F, Syrianen S, Syrianen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
5. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
6. Bodner S, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
7. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P. p53 and c-erbB-2 expression in breast carcinoma: an immunohistochemical study with correlations to receptor status, proliferation markers, and clinical stage in human breast carcinoma. Am J Clin Pathol 1992;98:408-18.
8. Battifora H. p53 Immunohistochemistry: a word of caution. Hum Pathol 1994;25:435-7.
9. Dei Tos AP, Doglioni C, Barbareschi M, Laurino L, Fletcher C. p53 expression in soft tissue lesions. Histopathology 1993;22:45-50.
10. Cristofolini M, Boi S, Girlando S, Dalla Palma P, Doglioni C, Barbareschi M. p53 protein expression in nevi and melanomas. Arch Dermatol 1993;129:739-43.
11. Barbareschi M, Iuzzolino P, Pennella A, Allegranza A, Dalla Palma P, Doglioni C. p53 protein expression in central nervous system neoplasms. J Clin Pathol 1992;45:583-6.
12. Iuzzolino P, Ghimenton C, Nicolato A, Fina P, Doglioni C, Barbareschi M. p53 protein in low grade astrocytomas: a study with long term follow-up. Br J Cancer 1994;69:586-91.
13. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
14. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
15. Allred DC, Clark GM, Fuqua SAW, et al. Overexpression of p53 in node positive breast cancer [Abstract]. Breast Cancer Res Treat 1993;27:131.
16. Andersen TI, Holm R, Nesland JM, Hiemdal KR, Ottestad L, Borresen AL. Prognostic significance of p53 alterations in breast carcinoma. Br J Cancer 1993;68:540-8.
17. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Hum Pathol 1993;24:469-76.
18. Friedrichs K, Gluba S, Eidtmann H, Jonath W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72: 3641-7.
19. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
20. MacGrogan G, Boinchon F, de Mascarel I, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71-81.
21. Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219:332-41.
22. Silvestrini R, Benini E, Daidone MG, et al. p53 as an independent prognostic marker in lymph node-negative cancer patients. J Natl Cancer Inst 1993;85:965-70.
23. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor protein: an independent marker in breast cancers. J Natl Cancer 1992;84:845-55.
24. Thorlacius S, Thorgilsson B, Björnsson J, et al. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 1995;31A:1856-61.
25. Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol 1995;57:96-104.
26. Cunningham JM, Ingle JN, Jung SH, et al. p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J Natl Cancer Inst 1994;86:1871-3.
27. Domagala W, Striker G, Szadowska A, Dokowicz A, Harazga B, Osborn M. p53 protein and vimentin in invasive ductal NOS breast carcinoma: relationship with survival and sites of metastases. Eur J Cancer 1994;30A:1527-34.
28. Gasparini G, Barbareschi M, Doglioni C, et al. Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1: 189-98.
29. Hurliman J. Prognostic value of p53 protein expression in breast carcinomas. Pathol Res Pract 1993;189:996-1003.
30. Iwaya K, Tsuda H, Hiraide H, et al. Nuclear p53 immunoreaction associated with prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-40.
31. Pietilainen T, Lipponene P, Aaltoma S, Eskelinen M, Kosma VM, Syrianen K. Expression of p53 protein has no independent value in breast cancer. J Pathol 1995;177:225-32.
32. Sawan A, Randall B, Angus B, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992;168:23-8.
33. Schimmelpenning H, Eriksson ET, Zetterbergh A, Auer GU. Association of immunohistochemical p53 tumor suppressor gene protein patient with prognosis in highly proliferative human mammary adenocarcinomas. World J Surg 1994;18:827-33.
34. Stenmark-Askmalm M, Stal O, Olsen K, Nordenskjold B, and the Southeast Sweden Breast Cancer Group. p53 as a prognostic factor in stage I breast cancer. Br J Cancer 1995; 72:715-9.
35. Visscher DW, Sarkar FH, Wykes S, Kothari K, Macoska J, Crissman J. Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Arch Pathol Lab Med 1993;117:973-6.
36. Barbareschi M, Caffo O, Veronese S, et al. Bcl2 and p53 expression in node negative breast carcinoma: a study with long term follow-up. Hum Pathol (in press).
37. Bland KI, Konstandulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein co-expression: value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995;6:726-0.
38. Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long term follow-up. Virchows Archiv A Pathol Anat 1992;421:291-5.
39. Elledge RM, Gray R, Mansour E, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant therapy with cyclophosphamide, methotrexate, fluoruracil and prednisone for breast cancer. J Natl Cancer Inst 1995;87: 1254-56.
40. Gambacorta M, Verderio P, Corletto V, Giardini R, Veronese S, Boracchi P. Multifactor prognostic evaluation of breast cancer [Abstract]. Pathol Res Pract 1995;191:670.
41. Haerslev T, Jacobsen GK. An immunohistochemical study of p53 protein with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum Pathol 1995;26:295-301.
42. Hanzal E, Gitsch G, Kohlberger P, Dadak C, Miechowieka N, Breitnecker G. Immunohistochemical detection of mutant p53 suppressor gene product in patients with breast cancer: influence on metastasis-free survival. Anticancer Res 1992;12:2325-9.
43. Jacquemier J, Penault-Llorca F, Vienes P, et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 194;14:2773-8.
44. Lipponen P, Ji H, Aaltomaa S, Syriänen S, Syriänen K. p53 Protein expression in breast cancer as related to histopathologic characteristics and prognosis. Int J Cancer 1993;55: 51-6.
45. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991;164:75-81.
46. Poller DN, Hutchinson CE, Galea M, et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptors. Br J Cancer 1992; 66:583-8.
47. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995;13:821-30.
48. Schönborn I, Minguillon C, Möhner M, Ebeling K. Value of new prognostic factors in lymph node-negative breast cancer [Abstract]. Eur J Cancer 1995;31A:suppl. 5:s142.
49. Stenmark-Askmalm M, Stal O, Sullivan S, et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 1994;30A:175-80.
50. Lowe SW, Bodis S, Mcclatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-11.
51. Tenaud C, Negoescu A, Labatmoleur F, Legros Y, Soussi T, Brambilla E. Methods in pathology. p53 immunolabeling in archival paraffin-embedded tissues: optimal protocols based on microwave heating for eight antibodies on lung carcinomas. Mod Pathol 1994;7:853-9.
52. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
53. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995;177: 221-4.
54. Mcilwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrest and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994;54:3718-22.
55. Milner J. DNA damage, p53 and anticancer therapies. Nature Med 1995;1:879-8.
56. Jacquemier J, Moles JP, Penault-Ljorca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994;69:846-52.
57. McKee PH, Hobbs C, Hall PA. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 1993;23:377-9.
58. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31.
59. Kerns BM, Jordan PA, Moore MH, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40: 1047-52.
60. Cattoretti G, Becker MH, Key G, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin fixed paraffin sections. J Pathol 1992; 168:357-63.
61. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? Revisited! J Pathol 1994;172:1-4.
62. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-9.
63. Marchetti A, Buttitta F, Girlando S, et al. Mdm2 gene alterations and mdm2 protein overexpression in breast carcinomas. J Pathol 1995;175:31-8.
64. Doglioni C, Barbareschi M, Pelosio P. Immunohistochemistry of tumor suppressor gene products. Surg Pathol 1995;6: 129-46.
65. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metast Rev 1995;14:3-15.
66. Koechli OR, Schaer GN, Seifert B, et al. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994;344:1647-8.
67. Faille A, De Cremoux P, Extra JM, et al. p53 mutations and overexpression in locally advanced breast cancer. Br J Cancer 1994;69:1145-50.
68. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995;1:1029-34.
69. Rusch V, Klimstra D, Vekatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell cancer. Cancer Res 1995;55:5038-42.
70. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009-11.
71. Archer SG, Eliopulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72:1259-66.
72. Makris A, Powles TJ, Dowsett M, Allred C. p53 overexpression and chemosensitivity in breast cancer. Lancet 1995;345: 1181-2.
73. Mathieu MC, Koscienly S, Le Bihan ML, Spielman M, Arrigada R. p53 protein overexpression and chemosensitivity in breast cancer. Lancet 1995;345:1182.
74. Sta°hl O, Stenmark-Askmalm M, Wingren S, et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995;34:767-70.
75. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1.
76. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995;36:119-26.
77. Van Meier EG, Polverini PJ, Chazin VR, Huang HJS, Detribolet N, Cayenne WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994;8:171-6.
78. Kieser A, Wiech HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9: 963-9.
79. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumour. Nature 1996;379:19-20.
80. Graeber T, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
81. Harris AL, Doglioni C, Bonzanini M, Barbareschi M. Necrosis in human breast tumours and p53 expression. (submitted).
82. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45.
83. Olson DC, Marechal V, Momad J, Chen J, Romocki C, Levine AJ. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993;8:2353-60.
84. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1: a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
85. Cordon-Cardo C, Latres E, Drobjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
86. Lianes P, Orlow I, Zeng ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325-30.
87. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
88. Barbareschi M, Caffo O, Doglioni C, et al. p21Waf1 immunohistochemical expression in breast carcinoma: correlation with clinicopathologic data, ER status, MIB1 expression, p53 gene and protein alteration and relapse free survival. Br J Cancer (in press).
89. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21WAF1 and p53 expression in breast carcinoma: an immunohistochemical study on 261 cases with long term follow up. (submitted).
90. Banks L, Matlashewskj G, Crawford L. Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-34.
91. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
92. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of human p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Meth 1992;151:237-44.
93. Bartek J, Barkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 1993;169:27-34.
94. Midgley CA, Fisher CJ, Bartek J, Voitesek B, Lane D, Barnes DM. Expression of human p53 in bacteria: applications to the analysis of p53 expression in human tumors. J Cell Sci 1992;101:183-9.
95. Pezzella F, Micklem K, Turley H, et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 1994;47:592-6.